DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
AZD-1480 is an investigational drug.
There have been 30 clinical trials for AZD-1480. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2010.
The most common disease conditions in clinical trials are Adenocarcinoma, Ovarian Neoplasms, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.
There are ten US patents protecting this investigational drug and seventy-seven international patents.
Recent Clinical Trials for AZD-1480
|Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||National Cancer Institute (NCI)||Phase 2|
|Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||M.D. Anderson Cancer Center||Phase 2|
|Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer||AstraZeneca||Phase 2|
Top disease conditions for AZD-1480
Top clinical trial sponsors for AZD-1480
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AZD-1480||Start Trial||Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections||EMORY UNIVERSITY (Atlanta, GA)||Start Trial|
|AZD-1480||Start Trial||Compounds and methods for inhibiting JAK||Dizal (Jiangsu) Pharmaceutical Co., Ltd. (Wuxi, Jiangsu Province, CN)||Start Trial|
|AZD-1480||Start Trial||Formylated N-heterocyclic derivatives as FGFR4 inhibitors||NOVARTIS AG (Basel, CH)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|